Omalizumab (Xolair) maintained efficacy for chronic rhinosinusitis with nasal polyps, a researcher reported.
In an open-label extension study of two, 24-week clinical trials, omalizumab was associated with significant improvements in nasal polyp scores (mean change -0.97, 95% CI -1.25 to -0.69), nasal congestion scores (mean change -0.99, 95% CI -1.14 to -0.83), and Sino-Nasal Outcome Test (SNOT) scores (mean change -22.39, 95% CI -25.39 to -19.40) through 1 year, according to Philippe Gevaert, MD, PhD, of Ghent University in Belgium.
“Scores worsened following omalizumab withdrawal, but remained above pre-treatment levels at week 76,” Gevaert said during a presentation at the American College of Allergy, Asthma & Immunology virtual meeting.
Omalizumab is thought to bind to free local immunoglobulin E (IgE), reducing inflammation that occurs with nasal polyps, Gevaert said.
Currently, dupilumab (Dupixent) is the only FDA-approved therapy to treat chronic rhinosinusitis with nasal polyps, and omalizumab is approved for treating moderate to severe persistent asthma.
The FDA did accept a supplemental biologics license application for this indication in 2019, but the application has not yet been reviewed due to the COVID-19 pandemic, noted Joseph Han, MD, of the Eastern Virginia Medical School in Norfolk, during a discussion of the findings.
Han added that he suspects “we may be able to find a decision soon.”
The European Commission approved omalizumab as an add-on therapy to intranasal corticosteroids for treating severe and persistent chronic rhinosinusitis with nasal polyps in August 2020.
Patients on either omalizumab or placebo in the original POLYP 1 and POLYP 2 studies were enrolled in this extension trial after 24 weeks. All patients then received 28 weeks of treatment followed by another 24 weeks of follow-up, during which they were only receiving background nasal spray.
The most common adverse event during the treatment period was nasopharyngitis, which occurred in 4.8% of patients. Otherwise the drug was well-tolerated, Gevaert said.
Overall, 95.6% of patients completed the extension treatment period and 92.8% completed the follow-up. Patients originally on placebo showed a similar treatment response to patients who continued omalizumab treatment from the previous study.
Many patients in the trial had surgery before entering the trial, but there was no difference in any of the outcomes when comparing patients with or without surgery, Gevaert said.
“In order to be included in the trial, you had to have a combined nasal polyp score of at least 5,” Gevaert said. “So although patients had surgery before, there was a regrowth of polyp large enough for them to be included in the trial.”
Disclosures
Gevaert disclosed relevant relationships with ALK, Argenx, AstraZeneca, Genentech, Hal Allergy, Novartis, Regeneron, Roche, Sanofi, and Stallergenes.
Co-authors disclosed multiple relevant relationships with industry including Genentech.
Related Post
Mar
Why Are Cancer Rates Rising in Adults Under 50?
One of the most widely recognized risk factors for disease is something we can't hope to make any significant difference with age. Our disease risk increments as we age, with the typical age at conclusion drifting around 68. Yet, another concentrate.
Read MoreFeb
World Mental Health Day 2023
World Emotional wellness Day 2023 is a chance for individuals and networks to join behind the subject 'Psychological well-being is a general basic freedom" to further develop information, bring issues to light and drive activities that advance and safeguard everybody's.
Read MoreFeb
Benefits of Celery Juice: A Comprehensive Review Based on Scientific Research
In the first place, celery is brimming with supplements, like potassium, calcium, and nutrients, and is loaded with a plenty of cell reinforcements. As a matter of fact, a solitary stem of celery contains no less than 12 unique antioxidantsTrusted.
Read MoreFeb
The Health Benefits of Deep Breathing (and 4 Easy Techniques!)
Breathing is a characteristic and compulsory activity that occurs for our bodies to take in and discharge air. An expected activity assists our bodies with working through daily existence. Breathing assists our respiratory framework with moving oxygen in and out,.
Read More